Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer

Sara A Hurvitz, Reva KakkarDepartment of Medicine, University of California, Los Angeles, CA, USAPurpose: This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents in the treatment of human epidermal growth fac...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hurvitz SA, Kakkar R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/87e80cf377974dfe9bec9c5365afb926
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:87e80cf377974dfe9bec9c5365afb926
record_format	dspace
spelling	oai:doaj.org-article:87e80cf377974dfe9bec9c5365afb9262021-12-02T05:19:20ZRole of lapatinib alone or in combination in the treatment of HER2-positive breast cancer1179-1314https://doaj.org/article/87e80cf377974dfe9bec9c5365afb9262012-04-01T00:00:00Zhttp://www.dovepress.com/role-of-lapatinib-alone-or-in-combination-in-the-treatment-of-her2-pos-a9624https://doaj.org/toc/1179-1314Sara A Hurvitz, Reva KakkarDepartment of Medicine, University of California, Los Angeles, CA, USAPurpose: This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents in the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer.Background: HER2-positive (HER2+) breast cancer remains a treatment challenge. It is more aggressive than other breast cancers and it is associated with a poor outcome. Targeted therapy for HER2+ breast cancer has significantly changed the clinical course of the disease. Despite advances in therapy, there remains an unmet need in the treatment of HER2+ breast cancer. Lapatinib is a novel, orally bioavailable epidermal growth factor receptor/HER2+ targeted agent. Many trials have investigated the efficacy and safety of lapatinib alone and in conjunction with other agents in the treatment of HER2+ breast cancer.Methods and results: Preclinical and clinical trials of lapatinib have shown that it is effective in the treatment on HER2+ breast cancer. More important, studies show that it is effective in the setting of trastuzumab resistance and in the treatment of central nervous system metastases, both of which are current treatment challenges. Furthermore, lapatinib is effective in conjunction with trastuzumab in the treatment of early breast cancer. Data regarding the safety of lapatinib show that it is generally well tolerated; however, multiple studies have shown significant (grade 3 and 4) diarrhea and rash associated with lapatinib, thereby limiting its use. Carditoxicity has not been a significant adverse event associated with the use of lapatinib.Conclusion: Lapatinib is effective alone and in conjunction with other agents in the treatment of HER2+ breast cancer. However, its use is limited by significant diarrhea and rash.Keywords: human epidermal growth factor receptor 2, breast neoplasms, central nervous system metastases, trastuzumabHurvitz SAKakkar RDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 35-51 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hurvitz SA Kakkar R Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
description	Sara A Hurvitz, Reva KakkarDepartment of Medicine, University of California, Los Angeles, CA, USAPurpose: This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents in the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer.Background: HER2-positive (HER2+) breast cancer remains a treatment challenge. It is more aggressive than other breast cancers and it is associated with a poor outcome. Targeted therapy for HER2+ breast cancer has significantly changed the clinical course of the disease. Despite advances in therapy, there remains an unmet need in the treatment of HER2+ breast cancer. Lapatinib is a novel, orally bioavailable epidermal growth factor receptor/HER2+ targeted agent. Many trials have investigated the efficacy and safety of lapatinib alone and in conjunction with other agents in the treatment of HER2+ breast cancer.Methods and results: Preclinical and clinical trials of lapatinib have shown that it is effective in the treatment on HER2+ breast cancer. More important, studies show that it is effective in the setting of trastuzumab resistance and in the treatment of central nervous system metastases, both of which are current treatment challenges. Furthermore, lapatinib is effective in conjunction with trastuzumab in the treatment of early breast cancer. Data regarding the safety of lapatinib show that it is generally well tolerated; however, multiple studies have shown significant (grade 3 and 4) diarrhea and rash associated with lapatinib, thereby limiting its use. Carditoxicity has not been a significant adverse event associated with the use of lapatinib.Conclusion: Lapatinib is effective alone and in conjunction with other agents in the treatment of HER2+ breast cancer. However, its use is limited by significant diarrhea and rash.Keywords: human epidermal growth factor receptor 2, breast neoplasms, central nervous system metastases, trastuzumab
format	article
author	Hurvitz SA Kakkar R
author_facet	Hurvitz SA Kakkar R
author_sort	Hurvitz SA
title	Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
title_short	Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
title_full	Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
title_fullStr	Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
title_full_unstemmed	Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
title_sort	role of lapatinib alone or in combination in the treatment of her2-positive breast cancer
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/87e80cf377974dfe9bec9c5365afb926
work_keys_str_mv	AT hurvitzsa roleoflapatinibaloneorincombinationinthetreatmentofher2positivebreastcancer AT kakkarr roleoflapatinibaloneorincombinationinthetreatmentofher2positivebreastcancer
_version_	1718400481393377280

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer

Ejemplares similares